https://www.business-standard.com/amp/companies/news/biocon-biologics-yesintek-us-market-access-approval-125050500182_1.html
Biocon Biologics' biosimilar Yesintek is approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, and...
biocon biologicsmarket accessmultiplecoverageyesintek